Department of Pediatrics, Washington University School of Medicine, 1 Children's Place, St. Louis, MO 63110, USA.
J Heart Lung Transplant. 2009 Nov;28(11):1221-5. doi: 10.1016/j.healun.2009.07.010. Epub 2009 Sep 26.
Certain congenital heart lesions in children can lead to irreversible lung disease thus making lung transplantation a therapeutic option. We retrospectively analyzed our experience with lung transplantation in 32 children with three distinct underlying congenital heart defects: (1) Eisenmenger syndrome (EIS); (2) tetralogy of Fallot with pulmonary atresia (PA); and (3) pulmonary vein stenosis (PVS).
Pediatric patients <18 years of age with either EIS (n = 7), PA (n = 8) or PVS (n = 17), who underwent lung or heart-lung transplantation, were analyzed. We compared survival rates between the three groups. Pre- and peri-operative variables were also assessed for their effect on outcome.
Compared with EIS and PA patients, PVS patients were younger and sicker at the time of transplantation. All EIS and PA patients required either additional intracardiac repairs or a heart transplant at the time of lung transplantation. PA patients had the highest rate of major post-operative complications and in-hospital deaths. Median survival was comparable between EIS (6.1 years) and PVS (6.5 years) patients. Outcomes for PA patients were dramatically worse, with a median survival of only 0.12 year ( approximately 47 days). Needing additional intracardiac surgery or a heart transplant at the time of lung transplantation did not impact survival. The diagnosis of PA itself correlated with a worse outcome.
Outcomes in EIS and PVS patients undergoing lung transplantation compare favorably to that of all pediatric lung transplant recipients (median survival 4.3 years). For PA patients, their underlying pathology appears to make them high-risk candidates for lung transplantation. For the younger and acutely sicker PVS patients, lung transplantation is a viable therapeutic alternative.
某些儿童先天性心脏病变可导致不可逆性肺疾病,从而使肺移植成为一种治疗选择。我们回顾性分析了 32 例患有三种不同基础先天性心脏病(1)艾森曼格综合征(EIS);(2)法洛四联症伴肺动脉闭锁(PA);和(3)肺静脉狭窄(PVS)的儿童进行肺移植的经验。
分析了<18 岁且患有 EIS(n=7)、PA(n=8)或 PVS(n=17)的小儿患者,他们接受了肺或心肺移植。我们比较了三组的生存率。还评估了术前和围手术期变量对结果的影响。
与 EIS 和 PA 患者相比,PVS 患者在移植时年龄更小,病情更严重。所有 EIS 和 PA 患者在进行肺移植时都需要进行额外的心脏内修复或心脏移植。PA 患者术后并发症和院内死亡的发生率最高。EIS(6.1 年)和 PVS(6.5 年)患者的中位生存期相似。PA 患者的预后明显更差,中位生存期仅为 0.12 年(约 47 天)。在进行肺移植时需要进行额外的心脏内手术或心脏移植并不影响生存率。PA 的诊断本身与预后不良相关。
EIS 和 PVS 患者行肺移植的结局与所有儿科肺移植受者的结局相当(中位生存期 4.3 年)。对于 PA 患者,其基础病理似乎使他们成为肺移植的高危候选者。对于年龄更小且病情更严重的 PVS 患者,肺移植是一种可行的治疗选择。